Analysts predict that Neuronetics Inc (NASDAQ:STIM) will report earnings of ($0.41) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Neuronetics’ earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.41). Neuronetics reported earnings per share of ($0.29) in the same quarter last year, which would suggest a negative year-over-year growth rate of 41.4%. The company is expected to issue its next earnings report before the market opens on Tuesday, November 5th.
On average, analysts expect that Neuronetics will report full-year earnings of ($1.61) per share for the current financial year, with EPS estimates ranging from ($1.62) to ($1.59). For the next financial year, analysts anticipate that the firm will report earnings of ($1.61) per share, with EPS estimates ranging from ($1.73) to ($1.48). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Neuronetics.
Neuronetics (NASDAQ:STIM) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.04. The company had revenue of $16.57 million during the quarter, compared to analysts’ expectations of $15.80 million. Neuronetics had a negative return on equity of 37.75% and a negative net margin of 43.85%.
In other Neuronetics news, CEO Christopher Thatcher sold 20,000 shares of Neuronetics stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $10.74, for a total transaction of $214,800.00. 12.00% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its holdings in shares of Neuronetics by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 31,506 shares of the company’s stock valued at $394,000 after buying an additional 1,270 shares during the last quarter. Morgan Stanley raised its holdings in shares of Neuronetics by 5,765.4% in the second quarter. Morgan Stanley now owns 110,681 shares of the company’s stock valued at $1,385,000 after buying an additional 108,794 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Neuronetics by 4.6% in the second quarter. Northern Trust Corp now owns 133,618 shares of the company’s stock valued at $1,671,000 after buying an additional 5,877 shares during the last quarter. Wasatch Advisors Inc. raised its holdings in shares of Neuronetics by 21.2% in the second quarter. Wasatch Advisors Inc. now owns 380,398 shares of the company’s stock valued at $4,759,000 after buying an additional 66,444 shares during the last quarter. Finally, Cortina Asset Management LLC raised its holdings in shares of Neuronetics by 25.7% in the second quarter. Cortina Asset Management LLC now owns 380,717 shares of the company’s stock valued at $4,763,000 after buying an additional 77,949 shares during the last quarter. 79.97% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ STIM traded down $0.25 during midday trading on Friday, reaching $8.63. 68,900 shares of the company traded hands, compared to its average volume of 101,605. The firm has a market cap of $166.18 million, a PE ratio of -3.21 and a beta of 0.94. The stock’s 50-day simple moving average is $9.69 and its 200-day simple moving average is $12.00. Neuronetics has a 12 month low of $7.94 and a 12 month high of $27.36. The company has a debt-to-equity ratio of 0.51, a quick ratio of 5.95 and a current ratio of 6.10.
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.